


myllia.






Q1 2026

**Design of sgRNA libraries for
CRISPRn screens**




The sgRNA design algorithm for CRISPRn screens

Training dataset of ~46,000 sgRNAs from published and in-house data sources




... and additional features

Convolutional neural network model



● Myllia (4) ☒☒☒☒

CRISPRn (indel formation)



Experimentally validate the sgRNA activity on both fitness & non-fitness phenotypes

Commonly used genome-scale sgRNA libraries for CRISPRn screens

GeCKO_v2

Correspondence | Published: 30 July 2014

Improved vectors and genome-wide libraries for CRISPR screening

[Neville E. Sanjana](#), [Ophir Shalem](#) & [Feng Zhang](#) 






TKO_v3

Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens

Traver Hart,^{*1} Amy Hin Yan Tong,[†] Katie Chan,[†] Jolanda Van Leeuwen,[†] Ashwin Seetharaman,[†] Michael Aregger,[†] Megha Chandrashekhar,[†] Nicole Hustedt,[‡] Sahil Seth,[§] Avery Noonan,[†] Andrea Habsid,[†] Olga Sizova,[†] Lyudmila Nedyalkova,[†] Ryan Climie,[†] Leanne Tworzanski,[†] Keith Lawson,[†] Maria Augusta Sartori,[†] Sabriyeh Alibeh,[†] David Tieu,^{†,**} Sanna Masud,^{†,**} Patricia Mero,[†] Alexander Weiss,[†] Kevin R. Brown,[†] Matej Usaj,[†] Maximilian Billmann,^{**} Mahfuzur Rahman,^{**} Michael Costanzo,[†] Chad L. Myers,^{**} Brenda J. Andrews,^{†,**,**} Charles Boone,^{†,**,**} Daniel Durocher,^{†,**} and Jason Moffat^{†,**,**,1}

Brunello

Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

Kendall R. Sanson¹, Ruth E. Hanna¹, Mudra Hegde ¹, Katherine F. Donovan¹, Christine Strand ¹, Meagan E. Sullender ¹, Emma W. Vaimberg¹, Amy Goodale¹, David E. Root¹, Federica Piccioni ¹ & John G. Doench ¹

Behan

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens

Fiona M. Behan^{1,2,12}, Francesco Iorio^{1,2,3,12}, Gabriele Picco^{1,12}, Emanuel Gonçalves¹, Charlotte M. Beaver¹, Giorgia Migliardi^{4,5}, Rita Santos⁶, Yanhua Rao⁷, Francesco Sassi⁴, Marika Pinnelli^{4,5}, Rizwan Ansari¹, Sarah Harper¹, David Adam Jackson¹, Rebecca McRae¹, Rachel Pooley⁴, Piers Wilkinson¹, Dieudonne van der Meer¹, David Dow^{2,6}, Carolyn Buser-Doepner^{2,7}, Andrea Bertotti^{4,5}, Livio Trusolino^{4,5}, Euan A. Stronach^{2,6}, Julio Saez-Rodriguez^{2,3,8,9,10}, Kosuke Yusa^{1,2,11,13*} & Mathew J. Garnett^{1,2,13*}


VBC

Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles


Georg Michlits^{1,4}, Julian Jude ^{2,4}, Matthias Hinterdorfer², Melanie de Almeida ², Gintautas Vainorius¹, Maria Hubmann¹, Tobias Neumann ², Alexander Schleiffer ^{1,2}, Thomas Rainer Burkard ^{1,2}, Michaela Fellner², Max Gijsbertsen¹, Anna Traunbauer ², Johannes Zuber ^{2,3}  and Ulrich Elling ¹ 

MinLibCas9

Minimal genome-wide human CRISPR-Cas9 library

Emanuel Gonçalves¹, Mark Thomas¹, Fiona M. Behan¹, Gabriele Picco¹, Clare Pacini^{1,2}, Felicity Allen¹, Alessandro Vinceti³, Mamta Sharma¹, David A. Jackson¹, Stacey Price¹, Charlotte M. Beaver¹, Oliver Dovey David Parry-Smith¹, Francesco Iorio^{1,3}, Leopold Parts^{1,4}, Kosuke Yusa⁵ and Mathew J. Garnett^{1*} 

CRISPR screens to target essential and non-essential genes



Dropout screen based on essentiality


- 24 genes, ~50 sgRNAs/gene

CD59 FACS readout




- 9 genes, ~50 sgRNAs/gene

Ranking sgRNA activities based on the observed phenotypes

~ 50 sgRNAs against each gene to cover the CDS




Viability phenotype to assess sgRNA activities




* = significant difference to Myllia, U-test on normalized LFC
 *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001

FACS-based CRISPR screen to monitor CD59 localization




Biosynthesis of GPI in the endoplasmic reticulum



Maturation of GPI-anchored proteins



CD59 localization to evaluate sgRNAs for targeting non-essential genes



* = significant difference to Myllia, U-test on normalized LFC
 *p ≤ 0.05, **p ≤ 0.01,

- Myllia's sgRNA design algorithm selects highly active sgRNA sequences for CRISPR screening
- Our custom sgRNAs enable highly specific targeting of both essential and non-essential genes
- Our sgRNA designs appear to be superior to other publicly available libraries

Acknowledgements

myllia.

The Team at Myllia Biotechnology

Am Kanal 27
1110 Wien
Austria

Email info@myllia.com

